In conclusion, TCZ drug retention rates of 94.1% and 86.6% at months 6 and 12 respectively were concordant with previously conducted TCZ clinical studies and TCZ seemed to be effectively showing favorable DAS28-CRP response rates in routine clinical practice in patients with moderate to severe RA responding inadequately to csDMARDs and/or TNFis. The gene discussed is CRP; the disease is rheumatoid arthritis.